Clinical Scorecard: Shining a Light into the ADC Conjugation Black Box
At a Glance
| Category | Detail |
|---|---|
| Condition | Antibody-Drug Conjugates (ADCs) |
| Key Mechanisms | Hydrophobic interaction chromatography (HIC) for real-time monitoring of bioconjugation reactions. |
| Target Population | Patients requiring targeted cancer therapies using ADCs. |
| Care Setting | Pharmaceutical manufacturing and analytical development. |
Key Highlights
- Ammonium tartrate enhances HIC performance for ADC characterization.
- Real-time monitoring of drug-to-antibody ratio (DAR) and drug load distribution (DLD).
- Rapid 10 min HIC method developed for process analytical technology (PAT).
- Insight into dissolution rate limitations led to significant process efficiency gains.
- Real-time analytics can transform ADC manufacturing processes.
Guideline-Based Recommendations
Diagnosis
- Utilize HIC for characterizing ADCs and monitoring critical quality attributes.
Management
- Implement real-time HIC-MS coupling for ongoing process monitoring.
Monitoring & Follow-up
- Adopt PAT methods to enhance understanding of bioconjugation reactions.
Risks
- Traditional methods may overlook critical process dynamics leading to inefficiencies.
Patient & Prescribing Data
Patients with cancers treated by ADCs.
Improved process understanding can lead to better product quality and reduced costs.
Clinical Best Practices
- Continuous stirring of reaction mixtures to enhance dissolution rates.
- Use of ammonium tartrate for improved HIC separation in ADC analysis.
- Adoption of rapid analytical methods to monitor bioconjugation in real-time.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

About the Author(s)
James Strachan
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.